CA2145681A1 - Method for antogonizing inositol 1,4,5-triphosphate - Google Patents
Method for antogonizing inositol 1,4,5-triphosphateInfo
- Publication number
- CA2145681A1 CA2145681A1 CA002145681A CA2145681A CA2145681A1 CA 2145681 A1 CA2145681 A1 CA 2145681A1 CA 002145681 A CA002145681 A CA 002145681A CA 2145681 A CA2145681 A CA 2145681A CA 2145681 A1 CA2145681 A1 CA 2145681A1
- Authority
- CA
- Canada
- Prior art keywords
- inositol
- triphosphate
- calcium
- release
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Oligomers of formula (I) have been demonstrated to be effective antagonists of inositol 1,4,5-triphosphate (IP3) by com-petitively vying with IP3 for binding sites. By competitively inhibiting the activity of IP3, the oligomers of this invention can modulate the release of intracellular calcium and elicit the resultant physiological effects.
Description
~ W094/07~07 2 1 4 S ~ 8 I PCT/US93/08168 METHOD FOR ANTAGONIZING INOSITOL 1,4,5-TRISPHOSPHATE
BACKGROUND OF THE INVENTION
This application relates to a series of diamino benzenedisulfonic acid oligomers that have demonstrated an affinity for the receptor sites of inositol 1,4,5-triphosphate (IP3) and are, therefore useful in diminishing the bioactivity of IP3, especially with regard to its effect on the release of intracellular calcium ions.
DESCRIPTION OF THE PRIOR ART
The diamino benzenedisulfonic acid oligomers demonstrating utility as IP3 antagonists according to this invention are described in detail in the European Patent Application published January 22, 1992 under Publication No. 0467185 A2. In that publication, the oligomers of the present invention were described as having utility in the diagnosis and/or treatment of AIDS and AIDS related complex.
SUMMARY OF THE INVENTION
The invention herein disclosed relates to a method of inhibiting the activity of inositol 1,4,5-triphosphate (IP3) by occupying the receptor sites specific to IP3 with a compound of the formula:
BACKGROUND OF THE INVENTION
This application relates to a series of diamino benzenedisulfonic acid oligomers that have demonstrated an affinity for the receptor sites of inositol 1,4,5-triphosphate (IP3) and are, therefore useful in diminishing the bioactivity of IP3, especially with regard to its effect on the release of intracellular calcium ions.
DESCRIPTION OF THE PRIOR ART
The diamino benzenedisulfonic acid oligomers demonstrating utility as IP3 antagonists according to this invention are described in detail in the European Patent Application published January 22, 1992 under Publication No. 0467185 A2. In that publication, the oligomers of the present invention were described as having utility in the diagnosis and/or treatment of AIDS and AIDS related complex.
SUMMARY OF THE INVENTION
The invention herein disclosed relates to a method of inhibiting the activity of inositol 1,4,5-triphosphate (IP3) by occupying the receptor sites specific to IP3 with a compound of the formula:
2~ 8 l -2-S03~Na +
H3C~N~I ~NJ~N ~CH3 S03~Na +
-- --n wherein n is a whole number selected from the range of 5 to 20 inclusive and the pharmaceutically acceptable salts thereof.
., DETAILED DESCRIPTION OF THE INVENTION
Inositol 1,4,5-triphosphate (IP3) is a naturally occurring and active component of animal physiology. It is formed intracellularly upon the activation of cell-surface receptors linked to the enzyme phospholipase C. Once generated in sufficient quantities, IP3 acts to stimulate the release of calcium ions from storage organelles within the cell. In this role IP3 is characterized as a "second messenger". Depending upon the type of cell, the calcium released by IP3 ~unctions to stimulate a variety of physiologic processes such as smooth muscle contraction, histamine secretion and the hyperpolarization of nerve cells. Any compound or agent that can promote or interfere with the function of IP3, will promote or interfere with the generation of calcium ions and thereby elicit predictable pharmacological effects.
The process by which IP3 releases calcium ions begins with the binding of IP3 to a specific receptor protein located on an intracellular calcium storage compartment located typically on the endoplasmic reticulum. This receptor protein has been cloned and has been shown to form a calcium "channel" with unique structural properties when bound to IP3. Therefore, when IP3 binds with its receptor, a calcium channel is opened causing the release of calcium stored in the cell's endoplasmic reticulum. In turn, the released calcium will elicit the appropriate cellular response.
Heretofore, the only verified potent antagonist of the 5 IP3 receptor was heparin, a complex glycosaminoglycan. The diamino benzenedisulfonic acid oligomers of this invention also appear to antagonize the effects of IP3 by competing for the receptor site. In most cases, these compounds are more effective than heparin and demonstrate fewer secondary effects. In addition to providing utility as laboratory "tools" in evaluating the therapeutic potential of other IP3 receptor antagonists, the oligomers of this invention would also be administered to modulate IP3-induced calcium release and have a salutary effect on any number of disorders that are caused or exacerbated by an inordinately productive IP3 second messenger pathway.
EXPERIMENTALS
Measurement of IP3 Bindinq Cerebella from male Sprague-Dawley rats (200 g) were homogenized in 30 volumes of ice-cold buffer A (50 mM Tris, 1 mM dithiothreitol, 1 mM EDTA, pH 7.7 with HCl) with a polytron (setting 9 for 10 seconds). The tissue is then washed twice by centrifugation (20,000 x g, 15 minutes;
Sorvall 28-S., SS-34 rotor) and resuspended in 30 volumes of ice-cold buffer A.
For the binding assays, 1.5 ml eppendorf tubes containing 50 ~1 of test compound (made up as a lOx stock in water) or water, 50 ~1 [3H] IP3 (17Ci/mmol; Dupont-NEN;
usually made as a 25 nM (lOx) stock solution in buffer), and 350 ~1 of buffer B (buffer A with pH adjusted to 8.4) . on ice. Tubes for non-specific binding also contained 50 ~1 of non-radioactive IP3 (100 ~M stock (lOx); final concentration 10 ~M), with an appropriate reduction in the volume of buffer B. Reactions were initiated by the addition of 50 ~1 tissue to make the final volume 500 ~1, 214~681 ~
followed by vortex mixing. Samples were incubated on ice for 10 minutes and then were centrifuged (14,000 x g) in a microfuge (Eppendorf model 5415) for 5 minutes followed by aspiration of the supernatant fraction. The tissue pellets were solubilized overnight in 100 ~1 of Protosol (Dupont-NEN). After solubilization, 73 ~1 of glacial acetic acid were added to decrease chemiluminescence, and the mixture was transferred to scintillation vials. To these vials was added 7 ml of Ecoscint-A (National Diagnostics) and the radioactivity determined by li~uid scintillation spectrophotometry.
Specific binding was defined as the difference between total binding (radioactivity in the absence of test compound and cold IP3) and non-specific binding (radioactivity in the absence of test compound but in the presence of cold IP3). This number was taken as 100%
specific binding. Data points obtained with the test compounds were fit by a computer program (GraphPad-InPlot) to determine their inhibitory potency. The inhibitory potencies of the test compounds were expressed as the concentration of compound that produces 50~ inhibition of specific binding (the ICso value).
The binding data are presented in Table 1 and demonstrate that compounds within the scope of the present invention effectively compete for [3H] IP3 binding sites in rat cerebellar membranes. The compound identified as MDL
102,869 was the most potent competitor for binding with an IC50 of 50 nM, whereas low molecular weight heparin (5100 MW) had an IC50 of 74 nM. MDL 102,869 is the compound according to the claimed invention wherein n = 15.
The potency for binding also seems to correlate with the ability to antagonize IP3-induced calcium ion release.
Thus, 1 and 3 ~M of MDL 102,869 inhibited calcium ion release by 42 and 100~, respectively (see Fig. 1), whereas WO 94/07507 2 1 4 5 ~ 8 1 PCI/US93/08168 10 llM of heparin inhibited release by 9o%. MDL 101,828, which had an IC50 binding of 104 nM, inhibited IP3-induced calcium ion release by 72% at 3 micro moles. MDL 101,828 is the compound according to the claimed invention wherein n = 9.
BindingInhibition of Ins(1,4,5) P3-CompoundICso (nM)Induced Ca2+-release Heparin (low MW)74 9o% at 10 ~M
MDL 101,828 104 42% at 3 llM
MDL 102,869 50 42% at 1 llM
100% at 3 ~M
The tracing of Fig. 1, dramatically illustrates the IP3 inhibition data set forth in the third column of Table 1.
S03~Na +
O ~ O
~H H 4~H N ~CH3 S03~Na +
--n The y-axis represents the concentration of free calcium ions in arbitrary units. The tracing shows that two successive additions of 0.1 llM of IP3 stimulated similar amounts of calcium ion release from cerebellar microsomes.
The addition of 1 ~lM of MDL 102,869 stimulated a small increase of calcium ion for unknown reasons. In the presence of 102,869, however, calcium ion release stimulated by 0.1 ~lM of IP3 was inhibited by 42%. This inhibition was overcome by the addition of 1 llM of IP3, consistent with competitive antagonism by MDL 102,869.
H3C~N~I ~NJ~N ~CH3 S03~Na +
-- --n wherein n is a whole number selected from the range of 5 to 20 inclusive and the pharmaceutically acceptable salts thereof.
., DETAILED DESCRIPTION OF THE INVENTION
Inositol 1,4,5-triphosphate (IP3) is a naturally occurring and active component of animal physiology. It is formed intracellularly upon the activation of cell-surface receptors linked to the enzyme phospholipase C. Once generated in sufficient quantities, IP3 acts to stimulate the release of calcium ions from storage organelles within the cell. In this role IP3 is characterized as a "second messenger". Depending upon the type of cell, the calcium released by IP3 ~unctions to stimulate a variety of physiologic processes such as smooth muscle contraction, histamine secretion and the hyperpolarization of nerve cells. Any compound or agent that can promote or interfere with the function of IP3, will promote or interfere with the generation of calcium ions and thereby elicit predictable pharmacological effects.
The process by which IP3 releases calcium ions begins with the binding of IP3 to a specific receptor protein located on an intracellular calcium storage compartment located typically on the endoplasmic reticulum. This receptor protein has been cloned and has been shown to form a calcium "channel" with unique structural properties when bound to IP3. Therefore, when IP3 binds with its receptor, a calcium channel is opened causing the release of calcium stored in the cell's endoplasmic reticulum. In turn, the released calcium will elicit the appropriate cellular response.
Heretofore, the only verified potent antagonist of the 5 IP3 receptor was heparin, a complex glycosaminoglycan. The diamino benzenedisulfonic acid oligomers of this invention also appear to antagonize the effects of IP3 by competing for the receptor site. In most cases, these compounds are more effective than heparin and demonstrate fewer secondary effects. In addition to providing utility as laboratory "tools" in evaluating the therapeutic potential of other IP3 receptor antagonists, the oligomers of this invention would also be administered to modulate IP3-induced calcium release and have a salutary effect on any number of disorders that are caused or exacerbated by an inordinately productive IP3 second messenger pathway.
EXPERIMENTALS
Measurement of IP3 Bindinq Cerebella from male Sprague-Dawley rats (200 g) were homogenized in 30 volumes of ice-cold buffer A (50 mM Tris, 1 mM dithiothreitol, 1 mM EDTA, pH 7.7 with HCl) with a polytron (setting 9 for 10 seconds). The tissue is then washed twice by centrifugation (20,000 x g, 15 minutes;
Sorvall 28-S., SS-34 rotor) and resuspended in 30 volumes of ice-cold buffer A.
For the binding assays, 1.5 ml eppendorf tubes containing 50 ~1 of test compound (made up as a lOx stock in water) or water, 50 ~1 [3H] IP3 (17Ci/mmol; Dupont-NEN;
usually made as a 25 nM (lOx) stock solution in buffer), and 350 ~1 of buffer B (buffer A with pH adjusted to 8.4) . on ice. Tubes for non-specific binding also contained 50 ~1 of non-radioactive IP3 (100 ~M stock (lOx); final concentration 10 ~M), with an appropriate reduction in the volume of buffer B. Reactions were initiated by the addition of 50 ~1 tissue to make the final volume 500 ~1, 214~681 ~
followed by vortex mixing. Samples were incubated on ice for 10 minutes and then were centrifuged (14,000 x g) in a microfuge (Eppendorf model 5415) for 5 minutes followed by aspiration of the supernatant fraction. The tissue pellets were solubilized overnight in 100 ~1 of Protosol (Dupont-NEN). After solubilization, 73 ~1 of glacial acetic acid were added to decrease chemiluminescence, and the mixture was transferred to scintillation vials. To these vials was added 7 ml of Ecoscint-A (National Diagnostics) and the radioactivity determined by li~uid scintillation spectrophotometry.
Specific binding was defined as the difference between total binding (radioactivity in the absence of test compound and cold IP3) and non-specific binding (radioactivity in the absence of test compound but in the presence of cold IP3). This number was taken as 100%
specific binding. Data points obtained with the test compounds were fit by a computer program (GraphPad-InPlot) to determine their inhibitory potency. The inhibitory potencies of the test compounds were expressed as the concentration of compound that produces 50~ inhibition of specific binding (the ICso value).
The binding data are presented in Table 1 and demonstrate that compounds within the scope of the present invention effectively compete for [3H] IP3 binding sites in rat cerebellar membranes. The compound identified as MDL
102,869 was the most potent competitor for binding with an IC50 of 50 nM, whereas low molecular weight heparin (5100 MW) had an IC50 of 74 nM. MDL 102,869 is the compound according to the claimed invention wherein n = 15.
The potency for binding also seems to correlate with the ability to antagonize IP3-induced calcium ion release.
Thus, 1 and 3 ~M of MDL 102,869 inhibited calcium ion release by 42 and 100~, respectively (see Fig. 1), whereas WO 94/07507 2 1 4 5 ~ 8 1 PCI/US93/08168 10 llM of heparin inhibited release by 9o%. MDL 101,828, which had an IC50 binding of 104 nM, inhibited IP3-induced calcium ion release by 72% at 3 micro moles. MDL 101,828 is the compound according to the claimed invention wherein n = 9.
BindingInhibition of Ins(1,4,5) P3-CompoundICso (nM)Induced Ca2+-release Heparin (low MW)74 9o% at 10 ~M
MDL 101,828 104 42% at 3 llM
MDL 102,869 50 42% at 1 llM
100% at 3 ~M
The tracing of Fig. 1, dramatically illustrates the IP3 inhibition data set forth in the third column of Table 1.
S03~Na +
O ~ O
~H H 4~H N ~CH3 S03~Na +
--n The y-axis represents the concentration of free calcium ions in arbitrary units. The tracing shows that two successive additions of 0.1 llM of IP3 stimulated similar amounts of calcium ion release from cerebellar microsomes.
The addition of 1 ~lM of MDL 102,869 stimulated a small increase of calcium ion for unknown reasons. In the presence of 102,869, however, calcium ion release stimulated by 0.1 ~lM of IP3 was inhibited by 42%. This inhibition was overcome by the addition of 1 llM of IP3, consistent with competitive antagonism by MDL 102,869.
Claims (3)
1. The use in the manufacture of a medicament for inhibiting the activity of inositol 1,4,5-trisphosphate by occupying a receptor site specific to inositol 1,4,5-trisphosphate effected with a compound of the formula:
wherein n is a whole number within the range of 5-20 and the pharmaceutically acceptable salts thereof.
wherein n is a whole number within the range of 5-20 and the pharmaceutically acceptable salts thereof.
2. The use of a compound according to claim 1 wherein n is 9.
3. The use of a compound according to claim 1 wherein n is 15.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95239392A | 1992-09-28 | 1992-09-28 | |
| US07/952,393 | 1992-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2145681A1 true CA2145681A1 (en) | 1994-04-14 |
Family
ID=25492868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002145681A Abandoned CA2145681A1 (en) | 1992-09-28 | 1993-08-30 | Method for antogonizing inositol 1,4,5-triphosphate |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0661982A1 (en) |
| JP (1) | JPH08502068A (en) |
| KR (1) | KR950703347A (en) |
| AU (1) | AU670962B2 (en) |
| CA (1) | CA2145681A1 (en) |
| HU (1) | HUT70192A (en) |
| IL (1) | IL107066A (en) |
| MX (1) | MX9305933A (en) |
| NO (1) | NO951163L (en) |
| NZ (1) | NZ256178A (en) |
| TW (1) | TW260663B (en) |
| WO (1) | WO1994007507A1 (en) |
| ZA (1) | ZA936978B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2978995A (en) * | 1994-06-30 | 1996-01-25 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Methods for treating cell proliferative disorders by modulating signal transduction |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
| US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6083920A (en) * | 1995-12-21 | 2000-07-04 | Ayurcore, Inc. | Compositions for modulating intracellular inositol trisphosphate concentration |
| US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
| US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| PL330850A1 (en) * | 1996-06-27 | 1999-06-07 | Smithkline Beecham Corp | Antagonists of il-8 receptors |
| JP2000514789A (en) | 1996-06-27 | 2000-11-07 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
| DE60127703D1 (en) * | 2000-11-09 | 2007-05-16 | Contrimmune Biotechnology Inc | USE OF XESTOSPONGIN C TO TREAT OR PREVENT HIV INFECTION |
| BR112014005104A2 (en) | 2011-09-02 | 2017-07-04 | Salk Inst For Biological Studi | camkii, ip3r, calcineurin, p38 and mk2 / 3 inhibitors to treat bind metabolic disorders of obesity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB781479A (en) * | 1953-08-27 | 1957-08-21 | Ciba Ltd | New polyureas and process for making them |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
-
1993
- 1993-08-30 HU HU9500891A patent/HUT70192A/en unknown
- 1993-08-30 WO PCT/US1993/008168 patent/WO1994007507A1/en not_active Application Discontinuation
- 1993-08-30 EP EP93921252A patent/EP0661982A1/en not_active Ceased
- 1993-08-30 AU AU48417/93A patent/AU670962B2/en not_active Ceased
- 1993-08-30 NZ NZ256178A patent/NZ256178A/en unknown
- 1993-08-30 CA CA002145681A patent/CA2145681A1/en not_active Abandoned
- 1993-08-30 KR KR1019950701166A patent/KR950703347A/en not_active Application Discontinuation
- 1993-08-30 JP JP6509054A patent/JPH08502068A/en active Pending
- 1993-09-21 ZA ZA936978A patent/ZA936978B/en unknown
- 1993-09-22 TW TW082107787A patent/TW260663B/zh active
- 1993-09-22 IL IL107066A patent/IL107066A/en not_active IP Right Cessation
- 1993-09-27 MX MX9305933A patent/MX9305933A/en unknown
-
1995
- 1995-03-27 NO NO951163A patent/NO951163L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL107066A0 (en) | 1993-12-28 |
| JPH08502068A (en) | 1996-03-05 |
| HUT70192A (en) | 1995-09-28 |
| KR950703347A (en) | 1995-09-20 |
| EP0661982A1 (en) | 1995-07-12 |
| AU4841793A (en) | 1994-04-26 |
| NZ256178A (en) | 1997-03-24 |
| AU670962B2 (en) | 1996-08-08 |
| HU9500891D0 (en) | 1995-05-29 |
| TW260663B (en) | 1995-10-21 |
| ZA936978B (en) | 1994-04-18 |
| NO951163D0 (en) | 1995-03-27 |
| IL107066A (en) | 1998-01-04 |
| MX9305933A (en) | 1994-04-29 |
| NO951163L (en) | 1995-03-27 |
| WO1994007507A1 (en) | 1994-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silveira et al. | Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases | |
| Akera | Membrane Adenosinetriphosphatase: A Digitalis Receptor? The enzyme is a good model for receptor binding studies because of its known functional correlates. | |
| TWI268923B (en) | N6 heterocyclic 8-modified adenosine derivatives | |
| US5204329A (en) | Treatment of organ transplantation rejection | |
| CA2145681A1 (en) | Method for antogonizing inositol 1,4,5-triphosphate | |
| JP2002526443A (en) | Serotoninergic 5HT2 agonist for treating glaucoma | |
| CZ20012340A3 (en) | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | |
| JPH07508731A (en) | Quinuclidine derivatives as substance P antagonists | |
| EP1320364A1 (en) | The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity | |
| US5763492A (en) | Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors | |
| Łażewska et al. | Alkyl derivatives of 1, 3, 5-triazine as histamine H4 receptor ligands | |
| Harris et al. | Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain | |
| EP0641202A1 (en) | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease | |
| BRAUN et al. | The attenuation of epinephrine-dependent adenylate cyclase by adenosine and the characteristics of the adenosine stimulatory and inhibitory sites | |
| Yamashita et al. | NZ-105, a new 1, 4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta | |
| WO2002050080A1 (en) | Small molecules useful in the treatment of inflammatory disease | |
| JPH02503670A (en) | 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepino derivatives and 10-aza, 10-oxa and 10-thia analogs | |
| JP2003512607A (en) | Allosteric site of muscarinic receptor | |
| Lee et al. | Potent enhancement of [3H] nitrendipine binding in rat cerebral cortical and cardiac homogenates: a putative mechanism for the action of MDL 12,330 A. | |
| Zhang | Muscarinic receptors in developing rat colon | |
| Douglas et al. | Efficacy of octa-and heptapeptide antagonists of angiotensin II as inhibitors of angiotensin III binding in the rat adrenal glomerulosa | |
| DE3904795C2 (en) | Pharmaceutical preparation and its use | |
| Kaul et al. | Quantitative structure—pharmacokinetic relationship of a series of sulfonamides in the rat | |
| US4904673A (en) | Agent for treating bradycardia and bradyarrhythmia | |
| EP0230234B1 (en) | Use of imidazoquinazolines for the treatment and prevention of nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19990518 |